Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: quereux g. Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16. Nat Med. 2023. PMID: 37845511 Free PMC article. Clinical Trial.
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: quereux g. Nat Med. 2024 Feb;30(2):607. doi: 10.1038/s41591-023-02661-5. Nat Med. 2024. PMID: 37923838 Free PMC article. No abstract available.
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: quereux g. Nat Med. 2024 Mar;30(3):906. doi: 10.1038/s41591-023-02775-w. Nat Med. 2024. PMID: 38177857 Free PMC article. No abstract available.
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Kirkwood JM, Vecchio MD, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Kirkwood JM, et al. Among authors: quereux g. Future Oncol. 2024 May;20(15):959-968. doi: 10.2217/fon-2023-0977. Epub 2024 Feb 23. Future Oncol. 2024. PMID: 38390818 Free article. Review.
Early diagnosis of melanoma: a randomized trial assessing the impact of the transmission of photographs taken with a smartphone from the general practitioner to the dermatologist on the time to dermatological consultation.
Bouton C, Schmeltz H, Lévèque C, Gaultier A, Quereux G, Dreno B, Nguyen JM, Rat C. Bouton C, et al. Among authors: quereux g. BMC Health Serv Res. 2024 May 24;24(1):660. doi: 10.1186/s12913-024-11106-9. BMC Health Serv Res. 2024. PMID: 38783296 Free PMC article. Clinical Trial.
Promoting clinical research in community-based practice: Threats and opportunities.
Poizeau F, Maruani A, Staumont-Sallé D, Jouan N, Ly S, Schollhammer M, Reverte M, Dibao-Dina C, Duong TA, Matard B, Penso-Assathiany D, Dupuy A, Carriot M, Seï JF, Corgibet F, Guillot B, Barbarot S, Leducq S, Bertolotti A, Tannous J, Chaby G, Jullien D, Pépin E, Quéreux G, Beylot-Barry M, Chosidow O; Centre of Evidence of the French Society of Dermatology. Poizeau F, et al. Among authors: quereux g. Ann Dermatol Venereol. 2024 Apr 29;151(2):103272. doi: 10.1016/j.annder.2024.103272. Online ahead of print. Ann Dermatol Venereol. 2024. PMID: 38688174 Free article. No abstract available.
Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study).
Tzoumpa S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, El Aarbaoui T, Dereure O, Quereux G, Faiz S, de Vicq de Cumptich M, Ram-Wolff C, Janela-Lapert R, Guenova E, Lheure C, Le Corre Y, Adamski H, Blanchard M, Bonnet N, Amatore F, Grange F, Troin L, Bagot M, Beylot-Barry M. Tzoumpa S, et al. Among authors: quereux g. Br J Dermatol. 2024 Apr 25:ljae153. doi: 10.1093/bjd/ljae153. Online ahead of print. Br J Dermatol. 2024. PMID: 38660811 No abstract available.
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A; GCC group Groupe Cancérologie Cutanée – Cutaneous Oncology Group, the Ethical Group of the Société Française de Dermatologie French Dermatology Group. Amini-Adle M, et al. Among authors: quereux g. Ann Dermatol Venereol. 2024 Mar;151(1):103243. doi: 10.1016/j.annder.2023.103243. Epub 2024 Feb 6. Ann Dermatol Venereol. 2024. PMID: 38325268 No abstract available.
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, Prost-Squarcioni C, Labeille B, Picard-Dahan C, Chaby G, Richard MA, Tancrede-Bohin E, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Musette P, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V; French Reference Center for Autoimmune Blistering Diseases MALIBUL. Tedbirt B, et al. Among authors: quereux g. JAMA Dermatol. 2024 Mar 1;160(3):290-296. doi: 10.1001/jamadermatol.2023.5679. JAMA Dermatol. 2024. PMID: 38265821 Clinical Trial.
Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Hazard M, Duval F, Dutriaux C, Beylot-Barry M, Pham-Ledard A, Quereux G, Amini-Adle M, Heidelberger V, Aubin F, Saint-Jean M, Nardin C, Abed S, Leccia MT, Mansard S, Prey S, Khammari A, Dréno B, Gérard E. Hazard M, et al. Among authors: quereux g. J Neurol. 2024 Mar;271(3):1473-1482. doi: 10.1007/s00415-023-12105-2. Epub 2023 Dec 6. J Neurol. 2024. PMID: 38052771 No abstract available.
186 results